Study guide

9.2 Asthma & COPD

APC Intern Written Examination Exam

Track your progress as you read

Finished sections get a check mark.

1 Introduction & Exam Overview

1.1 Current Exam Facts 1.2 Pathway to General Registration 1.3 Restricted Open-Book Strategy (AMH & APF) 1.4 Scoring, Results & Appeals

2 Legal Framework: PBS & Medicine Schedules

2.1 PBS, Authority Prescriptions & Special Access Scheme 2.2 Schedules 2 & 3 (Pharmacy & Pharmacist Only Medicines) 2.3 Schedules 4 & 8 (Prescription Only & Controlled Drugs)

3 Legal Framework: Privacy, National Law & Pharmacy Board

3.1 Privacy, Confidentiality & Patient Rights 3.2 Health Practitioner National Law & Registration 3.3 Pharmacy Board Codes, Guidelines & Standards

4 Patient-Centred Medication Management

4.1 Assessing Clinical Situations & Treatment Options 4.2 Patient Factors: Adherence, Efficacy & Safety 4.3 Drug & Dosage-Form Factors 4.4 Culturally Responsive Medication Management

5 Primary Care & Judicious Use of Medicines

5.1 Primary Care & OTC Assessment 5.2 Judicious Use of Antimicrobials & High-Risk Agents 5.3 Non-Pharmacological Options & Evidence-Based OTC Choices

6 Dispensing & Clinical Appropriateness

6.1 Prescription Evaluation 6.2 Clinical Appropriateness Checks 6.3 Labelling, Packaging & Dispensing Standards 6.4 Communicating with Prescribers & Documenting Changes

7 Counselling & Acute Care

7.1 Patient-Centred Counselling 7.2 Confirming Understanding & Lifestyle Counselling 7.3 Acute Illness, Injury & Emergency Response

8 Therapeutics: Cardiovascular & Endocrine

8.1 Hypertension & Heart Failure 8.2 Ischaemic Heart Disease & Anticoagulation 8.3 Diabetes Medicines 8.4 Thyroid & Lipid Disorders

9 Therapeutics: Infection, Respiratory & Gastrointestinal

9.1 Anti-Infectives & Infection Management 9.2 Asthma & COPD 9.3 Gastrointestinal & Hepatic Conditions 9.4 Vaccination & Travel Health

10 Therapeutics: Neurology, Psychiatry & Pain

10.1 Epilepsy & Movement Disorders 10.2 Depression, Anxiety & Psychosis 10.3 Pain Management & Opioids 10.4 Migraine & Common Analgesics

11 Therapeutics: Special Populations & Systems

11.1 Women's Health, Contraception & Pregnancy 11.2 Dermatology, Ophthalmology & ENT 11.3 Renal/Hepatic Impairment & Dose Adjustment

12 Therapeutics: Rheumatology, Haematology, Urology, Oncology & Toxicology

12.1 Rheumatology: Gout, Osteoarthritis & Inflammatory Arthritis 12.2 Haematology: Anaemias & Blood Safety Monitoring 12.3 Urology & Men's Health 12.4 Oncology Support & Oral Anticancer Medicines 12.5 Toxicology & Poisoning Management

13 Monitoring: Clinical Review

13.1 Clinical Review Process 13.2 Interpreting Laboratory & Clinical Monitoring 13.3 Recommending Treatment Modifications

14 Monitoring: Safety & Adverse Drug Reactions

14.1 Adverse Drug Reactions & Reporting 14.2 Allergies, Sensitivities & Cross-Reactivity 14.3 High-Risk Medicines Monitoring

15 Compounding Medicines

15.1 Determining Required Formulations 15.2 Compounding Standards & Quality 15.3 Patient-Specific Preparations

16 Pharmaceutical Calculations

16.1 Dosage Calculations 16.2 Concentrations, Dilutions & Alligation 16.3 Half-Life & Basic Kinetic Calculations

17 Promote Health & Well-Being

17.1 National & Local Health Priorities 17.2 Screening Programs & Pharmacist Role 17.3 Culturally Responsive Promotion & Self-Sufficiency

9.2 Asthma & COPD

Key Takeaways Explain This Topic AI

Relievers (usually short-acting beta2-agonists or anti-inflammatory reliever strategies) treat symptoms; preventers (especially inhaled corticosteroids) treat airway inflammation — over-reliance on reliever alone signals poor control.

ICS adherence and correct device technique (including spacers for metered-dose inhalers) are the highest-yield counselling interventions in community asthma care.

MART (maintenance and reliever therapy) uses an ICS–formoterol inhaler for both daily control and symptom relief in selected stepwise regimens — counsel the dual role clearly.

COPD care emphasises smoking cessation, vaccination, inhaler technique, and stepwise dual/triple therapy concepts; oral corticosteroids are short courses for exacerbations, not indefinite maintenance.

Severe exacerbation red flags (speaking in words only, cyanosis, exhaustion, silent chest, altered consciousness) require emergency care, not another pharmacy delay.

Last updated: August 2026

9.2 Asthma & COPD

Quick Answer: Separate reliever (quick symptom relief) from preventer (anti-inflammatory control, usually inhaled corticosteroid). Fix device technique and adherence before assuming the medicine “does not work.” Support written action plans , short-course oral steroids only for prescribed exacerbations, smoking cessation in COPD and asthma, and emergency referral for life-threatening features. Confirm regimens and stepwise choices in AMH/Australian asthma and COPD pathways.

Respiratory medicines are high-frequency Intern Written content because they combine pharmacology, device skill, monitoring of control, and acute safety-netting (Competencies 3.1–3.3 and health promotion overlaps).

Asthma — pathophysiology framing for pharmacists

Asthma involves variable airflow limitation, airway inflammation, and hyper-responsiveness. Symptoms include wheeze, dyspnoea, chest tightness, and cough — often worse at night or with triggers (viral infection, allergens, exercise, smoke). Pharmacotherapy aims to:

  • Control inflammation (prevent exacerbations and remodelling risk)
  • Relieve acute bronchoconstriction safely
  • Minimise adverse effects and over-reliance on short-acting bronchodilators alone
  • Reliever versus preventer
  • Role Typical agents (examples) Purpose
  • Reliever Salbutamol (SABA); in MART, low-dose ICS–formoterol as reliever Rapid relief of breakthrough symptoms

Preventer Inhaled corticosteroids (e.g. budesonide, fluticasone, beclometasone); often combined with long-acting beta2-agonists (LABA) Daily (or regimen-defined) control of inflammation

Add-on controllers Long-acting muscarinic antagonists (LAMA) in selected severe asthma; leukotriene receptor antagonists; biologics (specialist) Step-up when control inadequate

Critical counselling point: Feeling well does not mean stop the preventer. Patients commonly abandon ICS when asymptomatic, then present with preventable exacerbations. Explain that preventers work on inflammation over days to weeks; relievers do not replace anti-inflammatory therapy.

ICS adherence and safety

Inhaled corticosteroids are the cornerstone of persistent asthma preventer therapy. Counselling:

  • Use every day as prescribed, even when well
  • Rinse mouth / spit after ICS (and ICS–LABA) to reduce oral candidiasis and dysphonia
  • Spacer use with pMDI can improve lung deposition and reduce oropharyngeal side effects

Do not escalate to oral corticosteroids for mild day-to-day symptoms without a plan — oral steroids have systemic toxicity

Local adverse effects (thrush, hoarse voice) are common and manageable; systemic effects are less at standard inhaled doses but still relevant at high doses long-term (bone, adrenal, skin) — monitor step-down when control allows.

MART concepts (high-level)

Maintenance and reliever therapy (MART) uses a single ICS–formoterol inhaler for both regular maintenance doses and as-needed relief, within approved stepwise asthma regimens. Formoterol’s onset supports reliever use; the ICS component delivers anti-inflammatory treatment with each relief actuation — addressing the problem of SABA-only overuse without steroid coverage.

Pharmacist counselling for MART:

  • Which inhaler is the MART device (do not mix with a separate SABA plan unless the written plan says so)
  • How many maintenance actuations daily
  • How to use extra actuations for symptoms and the maximum daily actuations before seeking urgent review
  • That MART is not “use only when wheezy” if a maintenance dose is prescribed

If a patient on MART still carries an old SABA and dual-uses chaotically, reconcile the plan — confusion causes both under-treatment and toxicity risk.

Device technique — the counselling that saves lives

Wrong technique is a leading cause of “treatment failure.” Always check technique at initiation, when control is poor, and at regular reviews.

Pressurised metered-dose inhaler (pMDI) essentials:

  • Shake (if required for product)
  • Exhale gently away from device
  • Seal lips; start slow deep inhalation as you actuate
  • Continue inhaling; hold breath ~5–10 seconds if able
  • Wait between actuations as directed

Prefer a spacer for most adults and children using pMDI for asthma/COPD rescue or ICS — reduces coordination demand and oropharyngeal deposition

Dry powder inhalers (DPI): require adequate inspiratory flow; counsel forceful deep inhalation, device-specific priming/loading, and moisture protection.

Soft mist inhalers: follow device-specific actuation and slow inhalation technique.

Never assume a patient “has been on this for years” means technique is correct. Ask them to demonstrate.

Spacers

Spacers (valved holding chambers) improve pMDI delivery. Key points:

  • Compatible mouthpiece/mask fit
  • One actuation into spacer at a time (unless specific product advice differs)
  • Tidal breathing or single breath-hold methods as taught

Regular cleaning per manufacturer to reduce electrostatic drug loss (avoid rough drying that increases static for some devices)

Replace when valves fail or device is damaged

Supplying a preventer without assessing spacer need for a poorly coordinated pMDI user is incomplete care.

Asthma action plans and oral corticosteroids

Written asthma action plans define green/yellow/red zones: usual medicines, how to step up, when to start oral corticosteroids if prescribed for home use, and when to call emergency services. Pharmacists reinforce the plan at dispensing and after exacerbations.

Oral corticosteroids (e.g. prednisolone short courses) are for acute exacerbations under a clinician plan — not daily maintenance for typical asthma. Counsel:

  • Exact dose and duration (often several days — confirm prescription)
  • Take in the morning with food if GI upset
  • Mood, sleep, glucose rises (especially diabetes), and infection risk awareness
  • Do not stop abruptly after longer courses without advice (adrenal suppression risk with prolonged therapy)
  • Severe asthma exacerbation — red flags

Urgent/emergency care (call emergency services / hospital), not “wait and see at home”:

  • Severe breathlessness, inability to complete sentences, exhaustion
  • Cyanosis, confusion, drowsiness
  • Silent chest, collapsing, oxygen desaturation if measured
  • Little or no response to reliever as directed
  • Parental concern in children with marked work of breathing, feeding refusal, or lethargy

While awaiting help, patients use reliever as per emergency plan (often via spacer) — but pharmacy delay must not replace ambulance activation.

COPD — community therapeutic concepts

Chronic obstructive pulmonary disease features persistent airflow limitation, usually from smoking or other exposures. Goals: reduce symptoms (dyspnoea, cough, sputum), prevent exacerbations, improve function, and address comorbidities.

Foundations before “more inhalers”

Smoking cessation — single most important disease-modifying intervention; offer brief advice, behavioural support, and pharmacotherapy (NRT, varenicline, bupropion as appropriate) every opportunity

Vaccination — influenza, COVID-19 per current schedules, and pneumococcal vaccination concepts for chronic lung disease (see Section 9.4)

  • Pulmonary rehabilitation and activity — refer when available
  • Inhaler technique and adherence — same critical counselling as asthma
  • Dual and triple therapy concepts (high-level)

COPD stepwise inhaled therapy commonly includes:

Bronchodilators : LABA and/or LAMA for symptom and exacerbation reduction

ICS-containing regimens in selected patients with higher exacerbation risk or asthma–COPD overlap features — not every COPD patient needs ICS

Triple therapy (ICS + LABA + LAMA) for patients who continue to exacerbate or remain highly symptomatic despite dual long-acting bronchodilation, per guideline criteria

Pharmacist role: ensure the patient understands which inhaler is for daily maintenance versus any short-acting reliever, check technique, watch for ICS thrush risk, and flag duplicate same-class inhalers from multiple prescribers.

COPD exacerbations

Exacerbations may need increased bronchodilators, short-course oral corticosteroids , and antibiotics only when bacterial infection criteria are met (purulent sputum with increased dyspnoea/volume patterns — follow clinical guidelines). Stewardship still applies: not every “bad day” is bacterial.

Red flags: severe dyspnoea, cyanosis, confusion, drowsiness, chest pain, haemoptysis, or failure to respond — emergency care.

Monitoring control

For asthma, ask about night waking, reliever frequency, activity limitation, and exacerbations. Frequent SABA refill without preventer use is a control failure signal — open a clinical conversation and recommend medical review. For COPD, track exacerbation frequency, dyspnoea, and inhaler possession ratios.

Exam mindset

Intern items often hinge on technique , preventer adherence , MART dual-role clarity , spacer use , short-course oral steroid limits , smoking cessation , and emergency red flags . Drug names matter, but process skills pass the exam.